Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet needNEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) (GLOBE NEWSWIRE) Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa (R
Cellphone evidence is expected to be the focus of today's proceedings at the Senzo Meyiwa trial, which is currently underway in the Pretoria high court.
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking.
The Centers for Medicare & Medicaid Services ("CMS") released the final rule on risk adjustment data validation ("RADV") audits of Medicare Advantage ("MA") organizations.